The use of GnRH agonists in precocious puberty

Mul, Dick; Hughes, Ieuan A.

doi:10.1530/eje-08-0814

Cited by 81 publications

(58 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Follow-up data examining long-term risks or side effects of puberty blockers used for the purpose of halting a normally occurring rather than precocious puberty in transgender youth have not been published, but extrapolation from follow-up studies of blockers used for precocious puberty show promising results, with no known untoward consequences. 48 The goal of pubertal suppression is to decrease the gonadal secretion of and end-organ effects of endogenous sex steroids. GnRH analogs are administered in the form of intramuscular or subcutaneous injections or subcutaneous implants.…”

Section: Pubertal Suppressionmentioning

confidence: 99%

Psychological and Medical Care of Gender Nonconforming Youth

Vance¹,

2014

View full text Add to dashboard Cite

This is the 5th in our series on Adolescent Health. abstract Gender nonconforming (GN) children and adolescents, collectively referred to as GN youth, may seek care to understand their internal gender identities, socially transition to their affirmed genders, and/or physically transition to their affirmed genders. Because general pediatricians are often the first point of contact with the health care system for GN youth, familiarity with the psychological and medical approaches to providing care for this population is crucial. The objective of this review is to provide an overview of existing clinical practice guidelines for GN youth. Such guidelines emphasize a multidisciplinary approach with collaboration of medical, mental health, and social services/advocacy providers. Appropriate training needs to be provided to promote comprehensive, culturally competent care to GN youth, a population that has traditionally been underserved and at risk for negative psychosocial outcomes.

show abstract

Section: Pubertal Suppressionmentioning

confidence: 99%

Psychological and Medical Care of Gender Nonconforming Youth

Vance¹,

2014

View full text Add to dashboard Cite

show abstract

“…Çalışmalarda boy kazancı 3-10 cm arasında değişmektedir (6). Olgumuzda da Triptorelin asetat tedavisi 28 günde bir 3.75 mg intramüsküler şekilde verilmiştir (7).…”

Section: Discussionunclassified

Santral Puberte Prekoks Tanılı Bir Çocukta Triptorelin Asetat İlişkili Anafilaksi: Olgu Sunumu

Köse¹,

Asilsoy²,

Böber³

et al. 2017

Asthma Allergy Immunol

View full text Add to dashboard Cite

“…These ultrastructure findings likely reflect the suppressive effects of leuprorelin on the synthesis of gonadotropins in the markedly stimulated gonadotropes 8 weeks after castration. Although the sustained treatment with GnRH agonists has been conventionally used to prevent the synthesis of gonadal sex steroids which potentially aggravate androgen-or estrogen-dependent diseases such as prostate cancer, endometriosis and uterine myomas (Barbieri 1992, Engel et al, 2007, the findings described above clearly proved the putative efficacy of GnRH agonists on the clinical application for suppressing the excessive secretion state of pituitary gonadotropins in diseases such as central precocious puberty in juveniles (Antoniazzi and Zamboni, 2004;Mul and Hughes, 2008). In summary, our present study demonstrated in detail the ultrastructural changes in the ER and Golgi apparatus of pituitary gonadotropes under the influence of a longacting depot formulation of the GnRH agonist, leuprorelin.…”

Section: Discussionmentioning

confidence: 99%

Sustained treatment with a GnRH agonist (leuprorelin) affects the ultrastructural characteristics of membranous organelles in male rat pituitary gonadotropes

Bochimoto

Koga

Sakai

et al. 2013

Archives of Histology and Cytology

View full text Add to dashboard Cite

Summary. Gonadotropin-releasing hormone (GnRH) agonists exert acutely stimulatory action on gonadotropes, but thereafter suppress paradoxically gonadotropin synthesis and release by receptor desensitization. To examine whether GnRH signaling affects the morphological characteristics in membranous organelles related to the synthesis of gonadotropin, we have analyzed the ultrastructural changes in the ER and Golgi apparatus of male rat pituitary gonadotropes during sustained treatment with a GnRH agonist, leuprorelin. In pituitary gonadotropes at 1 day after the onset of treatment, clusters of the tubuloreticular ER appeared, and the globular Golgi apparatus was transiently disassembled into isolated small-sized stacks. However, 1 week after the onset of the treatment, the tubuloreticular ER was seemingly converted to rough ER with regularly stacked sheets and the scattered Golgi stacks converged to form globular structures. In the following chronic phase of the treatment, the ER cisterns remained flattened and the trans-Golgi compartment appeared to be collapsed. Sustained treatment with leuprorelin could also restore the enlarged Golgi apparatus and expand the cisterns of the rough ER; a feature that was seen in hypertrophic gonadotropes of castrated rats. These findings indicated that the ultrastructure of the membranous organelles changed because of the chronic suppressive effects of leuprorelin on gonadotropes both in the physiological and stimulated states. The acute and chronic ultrastructural changes in the ER and Golgi apparatus during sustained leuprorelin treatment also suggests that GnRH signaling cross-talks with the regulation of the morphological characteristics in membranous organelles related to gonadotropin synthesis.

show abstract

The use of GnRH agonists in precocious puberty

Cited by 81 publications

References 38 publications

Psychological and Medical Care of Gender Nonconforming Youth

Psychological and Medical Care of Gender Nonconforming Youth

Santral Puberte Prekoks Tanılı Bir Çocukta Triptorelin Asetat İlişkili Anafilaksi: Olgu Sunumu

Sustained treatment with a GnRH agonist (leuprorelin) affects the ultrastructural characteristics of membranous organelles in male rat pituitary gonadotropes

Contact Info

Product

Resources

About